Cogentix Medical Inc  

(Public, NASDAQ:CGNT)   Watch this stock  
Find more results for NASDAQ:VSCI
-0.06 (-5.08%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.10 - 1.17
52 week 1.10 - 6.10
Open 1.15
Vol / Avg. 0.00/49,717.00
Mkt cap 29.33M
P/E     -
Div/yield     -
EPS -0.49
Shares 26.19M
Beta 1.25
Inst. own 30%
Nov 3, 2015
Q2 2016 Cogentix Medical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 10, 2015
Q1 2016 Cogentix Medical Inc Earnings Call
Aug 10, 2015
Q1 2016 Cogentix Medical Inc Earnings Release
Jul 31, 2015
Cogentix Medical Inc Annual Shareholders Meeting
Jul 31, 2015
Vision Sciences Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -32.01% -29.06%
Operating margin -28.81% -28.83%
EBITD margin - -27.78%
Return on average assets -26.24% -20.82%
Return on average equity -67.87% -42.87%
Employees 211 -
CDP Score - -


5420 Feltl Rd
MINNETONKA, MN 55343-7982
United States - Map
+1-952-4266140 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cogentix Medical, Inc., formerly Vision-Sciences, Inc., is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.

Officers and directors

Robert C. Kill Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Brett A. Reynolds Senior Vice President, Chief Financial Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Darin Hammers Senior Vice President - Global Sales and Marketing
Bio & Compensation  - Reuters
James P. Stauner Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth H. Paulus Director
Age: 55
Bio & Compensation  - Reuters
Cheryl Pegus M.D. Director
Age: 51
Bio & Compensation  - Reuters
Lewis C. Pell Director
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin H. Roche Director
Age: 63
Bio & Compensation  - Reuters